Reference : A multicentre, double-blind, randomized, placebo-controlled, parallel group study of ...
Scientific journals : Article
Human health sciences : Neurology
Social & behavioral sciences, psychology : Neurosciences & behavior
A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches
Relja, M. [> > > >]
Poole, A. C. [> > > >]
Schoenen, Jean mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie]
Pascual, J. [> > > >]
Lei, X. [> > > >]
Thompson, C. [> > > >]
Blackwell Science
Yes (verified by ORBi)
[en] botulinum toxin type A ; episodic migraine ; prophylaxis
[en] Our aim was to evaluate the safety and efficacy of botulinum toxin type A (BoNTA; BOTOX (R)) for prophylaxis of episodic migraine. In this double-blind, placebo-controlled study, patients were randomized to 225, 150 or 75 U of BoNTA or placebo after a 30-day placebo run-in for three 90-day treatment cycles. The primary efficacy end-point was the mean reduction from baseline in the frequency of migraine episodes at day 180 in the placebo non-responder stratum. All groups (N = 495) improved, with no significant differences. At day 180, the frequency of migraine episodes was reduced from baseline means of 4.3, 4.7, 4.7 and 4.4 by 1.6, 1.7, 1.5 and 1.4 for BoNTA 225 U, 150 U and 75 U and placebo, respectively. The primary end-point was not met. Treatment-related adverse events were transient and mild to moderate. BoNTA treatment was safe and well tolerated but did not result in significantly greater improvement than placebo in this study. Several factors may have confounded the results.

File(s) associated to this reference

Fulltext file(s):

Restricted access
A multicentre double blind Relja et al 2007.pdfPublisher postprint180.75 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.